Literature DB >> 2934022

Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth.

H J Zeiler.   

Abstract

Cells of Escherichia coli Neumann and E. coli KL16 were suspended in phosphate-buffered saline pH 7.4 and allowed to reach stationary growth conditions. Ciprofloxacin was added at different concentrations, and time-kill curves were constructed. It could be demonstrated that the number of viable cells was reduced quickly by several logs for E. coli Neumann, whereas a weak and slow killing effect was observed with E. coli KL16. When ciprofloxacin or norfloxacin was added to logarithmically growing cultures of E. coli Neumann or E. coli KL16, no principal differences in the killing rate for the two strains could be observed. Ciprofloxacin, however, was more bactericidal than norfloxacin. It was also demonstrated that the bactericidal action of ciprofloxacin on cells in the stationary growth phase was better at pH 7.4 than at pH 8.6. This dependence is different from that observed in MIC studies, in which the MIC were lower at pH 8.0 than at pH 7.2. It was also found that the bactericidal action of ciprofloxacin or norfloxacin on cells of E. coli Neumann in the stationary phase of growth could not be reduced by the addition of chloramphenicol, whereas under conditions of logarithmic growth the rapid killing effect of ciprofloxacin was reduced in the presence of chloramphenicol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934022      PMCID: PMC180297          DOI: 10.1128/AAC.28.4.524

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Investigations into the mechanism of action of the antibacterial agent norfloxacin.

Authors:  G C Crumplin; M Kenwright; T Hirst
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

2.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

3.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

5.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

6.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

7.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

  9 in total
  28 in total

1.  Comparative Activity of Ceftriaxone, Ciprofloxacin, and Gentamicin as a Function of Bacterial Growth Rate Probed by Escherichia coli Chromosome Replication in the Mouse Peritonitis Model.

Authors:  Maria Schei Haugan; Anders Løbner-Olesen; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 2.  Influence of growth rate on susceptibility to antimicrobial agents: modification of the cell envelope and batch and continuous culture studies.

Authors:  M R Brown; P J Collier; P Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

3.  Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella.

Authors:  M E Page-Clisson; H Pinto-Alphandary; E Chachaty; P Couvreur; A Andremont
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  D Bahl; D A Miller; I Leviton; P Gialanella; M J Wolin; W Liu; R Perkins; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  Ecotoxicological effects of ciprofloxacin on freshwater species: data integration and derivation of toxicity thresholds for risk assessment.

Authors:  N Martins; R Pereira; N Abrantes; J Pereira; F Gonçalves; C R Marques
Journal:  Ecotoxicology       Date:  2012-02-29       Impact factor: 2.823

6.  Quinolones and coumarins eliminate chloroplasts from Euglena gracilis.

Authors:  J Krajcovic; L Ebringer; J Polónyi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones.

Authors:  J S Wolfson; D C Hooper; D J Shih; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

8.  Identification of a pKM101 region which confers a slow growth rate and interferes with susceptibility to quinolone in Escherichia coli AB1157.

Authors:  B Clerch; E Rivera; M Llagostera
Journal:  J Bacteriol       Date:  1996-10       Impact factor: 3.490

Review 9.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

10.  Ciprofloxacin in combination with metronidazole.

Authors:  R Werk; L Schneider
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.